Immix Biopharma Details $100M ATM Offering, Discloses Initial $4.4M in Sales
IMMX has more than doubled off its 52-week low of $1.34.
Summary
Immix Biopharma filed a prospectus supplement detailing its At-The-Market (ATM) offering of up to $100 million in common stock and disclosed that it has already sold $4.4 million under the program.
Key Events · Financing and Capital Events · IMMX
-
Formalizes $100M At-The-Market Offering
Immix Biopharma has filed a prospectus supplement to formalize the terms of its At-The-Market (ATM) offering, allowing the company to sell up to $100 million in common stock from time to time through Citizens JMP Securities, LLC.
-
Discloses Initial Sales Under ATM Program
The company has already sold 1,697,504 shares of common stock pursuant to the ATM agreement, generating net proceeds of $4,409,430.
-
Significant Potential Dilution
If the full $100 million is sold at the assumed price of $9.11 per share, it would result in the issuance of approximately 10.98 million new shares, representing a substantial increase in outstanding shares and potential dilution for existing investors.
-
Proceeds for NXC-201 Development and Working Capital
The net proceeds from the offering are intended to fund NXC-201 development, working capital, and general corporate purposes, supporting the company's clinical pipeline and operations.
Analysis · IMMX · Life Sciences
This filing provides the formal terms and initial execution details for the At-The-Market (ATM) offering of up to $100 million, which was previously announced. For a clinical-stage biopharmaceutical company like Immix Biopharma, securing capital is critical for funding ongoing NXC-201 development and general corporate purposes, extending its operational runway. While the potential for up to $100 million in sales represents substantial dilution (approximately 20.7% based on current outstanding shares), the ability to raise these funds is a necessary step for the company's progress, especially following the recent FDA Breakthrough Therapy designation for NXC-201. Investors should monitor the pace and pricing of future ATM sales for further insights into capital needs and market reception.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $9.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.8M. The 52-week trading range was $1.34 to $11.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.